Hydrix Limited · ASX:HYD
Hydrix — Shareholder Meeting (November 2025)
16 slides from Hydrix's shareholder meeting presentation, Nov 27, 2025
Slide 1: Annual General Meeting 2025
For personal use only Annual General Meeting 2025 Thursday 27th November 2025
Slide 2: We create, deliver & invest in highly disruptive product innovation
For personal use only We create, deliver & invest in highly disruptive product innovation across global markets to empower People’s Lives
Slide 3: Emerging as an innovative medtech & cardiovascular health technology business
Emerging as an innovative medtech & cardiovascular For personal use only health technology business Tracking progress of our Buy, Build, Invest strategy 01 02 03 04 05 06 Acquire Hydrix Establish Hydrix Establish Hydrix Build Medical Group Revenue Group Services Ventures Medical Portfolio Growth Pro
Slide 4: International revenue growth strategy is succeeding
International revenue growth strategy is For personal use only succeeding 1 Expertise that outweighs distance Revenues International Australia 2 Business development located in USA + EUR + AUS 72% 64% 53% 57% 3 Global reputation for quality and innovation 26% 4 Point of difference in cardiovascular
Slide 5: Revenue growth, improving margins, lower costs to drive profit
Revenue growth, improving margins, For personal use only Sequential quarterly revenue growth on sustained lower operating lower costs to drive profit costs helping to bring the Group closer to a quarterly profit ($M’s) $3.0 $3.1 $3.1 Hydrix Group expenses Expenses Hydrix Services $2.6 $2.7 $2.6 Hydr
Slide 6: Key objectives next twelve months
Key objectives next twelve months For personal use only 1 Continue empowering Lives through innovation 2 Grow Services revenues to increase profit 3 Liquidity event to generate non-dilutive funds flow 4 Medical deliver first sales to generate recurring revenues 5 Drive topline revenue growth and exp
Slide 7: Hydrix Limited – Board of Directors
Hydrix Limited – Board of Directors For personal use only Mr Gavin Coote Mr Paul Wright Mr Paul Lewis Ms Julie King Ms Alyn Tai Executive Chairman Non-Executive Director Non-Executive Director Non-Executive Director Corporate Counsel Gavin has extensive executive Paul spent 18 years as CEO of Paul s
Slide 8: Corporate snapshot and capitalisation table
Corporate snapshot Capitalisation table For personal use only Major Shareholders Shares (m) % Capital Structure (as of 30 October 2025) John W. King & related entities 30.9 11.3 Ticker HYD Paul Lewis & related entities 20.4 7.5 Share Price $0.016 Pusen Medical Technology Australia Pty Ltd 12.0 4.4 S
Slide 9: Business recap
For personal use only We create, deliver & invest in highly disruptive product innovation across global markets Business recap to empower People’s Lives
Slide 10: FY25 Financial Overview
HYDRIX Services HYDRIX Ventures FY25 Financial • Revenues $10.1m (-5%), 65% • Net Asset value decreased by Overview For personal use only medtech, 17% cardiac $0.2m to $3.2m • 64% revenues from international • Net impact from Fair value • $35m future stage revenues adjustment of WaveWise across 15 a
Slide 11: We create the innovation in breakthrough technologies – Hydrix Services
We create the innovation For personal use only Market focus – Hydrix Services in breakthrough • Outsourced product development services - from concept to market technologies • Highly specialised and highly regulated new product development • Safety critical systems e.g., Class III active implantable
Slide 12: LUDO system testimonial, The Texas Heart Institute
"The LUDO system has proven an incredible asset for The Texas Heart Institute, providing us with everything essential for the success of For personal use only our LVAD projects” Yaxin Wang, PhD Associate Investigator Director, Innovative Device and Engineering Applications, The Texas Heart Institute
Slide 13: We invest in the innovation in breakthrough technologies
We invest in the innovation For personal use only Medical Venture Capital Investment Strategy in breakthrough • Selectively invest in clients developing breakthrough technologies technologies • Early stage, minority investment <5-years to commercialisation • Use liquidity events as a source of non-d
Slide 14: We deliver the innovation in breakthrough technologies – Hydrix Medical
We deliver the innovation For personal use only Market focus – Hydrix Medical in breakthrough • Cardiovascular disease afflicts 14% of the population; the leading cause of death technologies • Cardiac diagnostic & remote patient monitoring (RPM) using AI/ML devices • Revenue model: SaaS-based recurr
Slide 15: Disclaimer
Disclaimer For personal use only The material in this presentation has been prepared by Hydrix Limited (“Hydrix”) ACN 060 369 048 and is general background information about Hydrix's activities current at the date of this presentation. The information is given in summary form and does not purport to
Slide 16: For more information, please visit www.hydrix.com
For personal use only For more information, please visit: www.hydrix.com